Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04132388
Other study ID # IRB00050544
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date August 20, 2020
Est. completion date September 7, 2022

Study information

Verified date September 2022
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial impact and morbidity, but that doesn't mean that patients will necessarily be adherent to recommended treatments. Patients, especially those on chronic medication therapy, inevitably miss doses. They use too little or too much therapy. They may take medications too soon or too far apart. While adherence to injection treatments tend to be better than adherence to topical or oral treatment, adherence to injections may still be poor. Traditional methods for measuring medical adherence-including questionnaires, surveys, and diaries- tend to be unreliable overestimate adherence. Chemical markers are problematic because of the tendency for patients to use their medication right before visits, so called "white coat compliance." Our research team has pioneered the use of electronic monitoring devices which measure and record the date and time of medication events to assess adherence in dermatology. The study team have demonstrated the feasibility of using such monitors to measure adherence to adalimumab in patients with psoriasis. Although only a small study, it documented a broad range of how patients use adalimumab and found that adherence was poor in about half of the patients. While the impact of psoriasis on patients' lives is large, adherence is still poor. How adherent patients with hidradenitis are to weekly adalimumab treatment is not yet well characterized.


Description:

This is a prospective single-center open-label randomized 6 month study. There will not be a washout period. Treatment will be for 26 weeks. Subjects will have baseline disease severity assessments. Subjects will be instructed to take adalimumab according to the labelled dosing regimen. Subjects will be randomized to either standard-of-care or to an electronic reporting intervention. The reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit. Primary Endpoints: Adherence to adalimumab treatment


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 7, 2022
Est. primary completion date September 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Male and female subjects ages 18 - 70 - Diagnosis of HS for which adalimumab is indicated according to the adalimumab prescribing information. - All subjects must have a negative TB skin test according to prescribing guidelines. - Subjects must be starting adalimumab for the first time, prescribed by their dermatologist. Exclusion Criteria: - All experimental drugs or devices are to be discontinued at least 1 month prior to initiation of study therapy. - Subjects who are receiving biologic therapy with a potential therapeutic impact on hidradenitis within 3 months will be excluded. - Pregnant and nursing females will not be allowed in the study, and females of childbearing potential will have a pregnancy test at baseline. Females of childbearing potential must agree to use approved birth control methods for the duration of the study. - Subjects who have received live vaccines within a 3 month period prior to enrollment will also be excluded. - In addition, subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Electronic Reporting
The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
Drug:
Adalimumab
Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks

Locations

Country Name City State
United States Wake Forest Health Sciences Dermatology Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of days between each dose for all subjects assessment of adalimumab treatment week 12 post randomization
Primary Number of days between each dose for all subjects assessment of adalimumab treatment week 26 post randomization
Primary Percentage of patients who achieve adherence success percentage who have taken over 90% of correct doses of study drug week 12 post randomization
Primary Percentage of patients who achieve adherence success percentage who have taken over 90% of correct doses of study drug week 26 post randomization
Secondary Number of Doses Taken Measured by MEMs cap week 12 post randomization
Secondary Number of Doses Taken Measured by MEMs cap week 26 post randomization
Secondary Physician Global Assessment (PGA) Assessment score ranges from 0 to 5 with a higher score denoting a worse outcome. week 12 post randomization
Secondary Physician Global Assessment (PGA) Assessment score ranges from 0 to 5 with a higher score denoting a worse outcome. week 26 post randomization
Secondary Hidradentis Suppurativa Clinical Response (HiSCR) Hidradenitis Suppurativa Clinical Response (HiSCR) measures number of inflammatory lesions. week 12 post randomization
Secondary Hidradentis Suppurativa Clinical Response (HiSCR) Hidradenitis Suppurativa Clinical Response (HiSCR) measures number of inflammatory lesions. week 26 post randomization
Secondary Dermatology Life Quality Index (DLQI) Scale ranges from 0 to 30 with a higher rating denoting a worse outcome. week 12 post randomization
Secondary Dermatology Life Quality Index (DLQI) Scale ranges from 0 to 30 with a higher rating denoting a worse outcome. week 26 post randomization
Secondary Number of Doses Missed week 26 post randomization
Secondary Total Time in Study week 26 post randomization
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2